Eurozone finance ministers give green light for Bulgaria to use euro
Eurozone countries on Thursday gave Bulgaria the green light to use the euro, with Sofia set to introduce the common currency in January 2026.
Bulgaria is set to become the 21st EU member state to use the euro after finance ministers of eurozone countries gave their approval to the European Commission and the European Central Bank (ECB).
The commission backed the move earlier this month, concluding that Bulgaria fulfils the necessary requirements to join the monetary union.
The criteria for joining include price stability, sound public finances and stable exchange rates.
Bulgaria has been a member of the EU since 2007 and had previously planned to replace its national currency, the lev, with the euro in 2024, but the adoption was postponed due to a comparatively high inflation rate of 9.5% at the time.
The commission recently said it expects an inflation rate of 3.6% for Bulgaria in the current year and 1.8% in 2026.
In Bulgaria, the possible introduction of the euro has been accompanied by fierce protests.
According to an opinion poll conducted by the Bulgarian Mjara institute in May, more than half of adults (54.9%) are against the introduction of the euro in 2026, while 34.4% are in favour of joining.
The next step is for the finance ministers of all EU countries to approve the plans before EU leaders discuss Bulgaria's accession to the eurozone at the end of June.
Finally, after consulting the European Parliament and the ECB, the member states must adopt the necessary legal acts at finance minister level.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
32 minutes ago
- Business Upturn
AS Inbank entered into merger agreement with Inbank Ventures OÜ
Today, on 20 June 2025, AS Inbank entered into a notarial merger agreement with its 100% subsidiary Inbank Ventures OÜ. As a result of the merger, Inbank Ventures OÜ will cease to exist without liquidation and AS Inbank will become its legal successor. Inbank Ventures OÜ is operating as a holding company and provides IT support services within the Inbank Group. The purpose of the merger is to align the Group's legal structure with its actual business operations and to enhance organisational efficiency, while leaving the consolidated assets, rights, and obligations unchanged. The merger will enter into force following the receipt of the required approval from the Financial Supervision and Resolution Authority. The completion of the merger is expected to take place during the first quarter of 2026. The merger agreement is attached to this notice. Additionally, the merger agreement and other related documents (including the merger report) are available for review at the office of AS Inbank, located at Niine 11, Tallinn. Advertisement Inbank is a financial technology company with an EU banking license that connects merchants, consumers and financial institutions on its next generation embedded finance platform. Partnering with more than 5,600 merchants, Inbank has 941,000+ active contracts and collects deposits across 7 markets in Europe. Inbank bonds are listed on the Nasdaq Tallinn Stock Exchange. Additional information: Styv Solovjov AS Inbank Head of Investor Relations +372 5645 9738 [email protected] Attachment AS Inbank ja Inbank Ventures OÜ ühinemisleping Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
36 minutes ago
- Yahoo
Almost a Third of Eurozone's U.S. Trade Surplus Is Due to U.S. Firms, Says ECB
Almost a third of the eurozone's goods trade surplus with the U.S. is accounted for by sales of products manufactured by the affiliates of American businesses, which also account for most of the eurozone's deficit in the trade in services, the European Central Bank said Friday. In its latest Economic Bulletin, economists at the central bank said that should the activities carried out by those affiliates be moved back to the U.S. in response to higher tariffs or changes to U.S. tax policy, the eurozone economy would be smaller, but the impact on employment and incomes would likely be limited. Surging Silver Prices Prompt Americans to Empty Jewelry Boxes and Coin Jars Home Depot Bid Kicks Off Battle for $5 Billion Building-Products Company How Do You Build a $500 Million Coffee Chain? By Selling Matcha to Teens. The Real Message Andy Jassy Is Sending to Employees on AI Don't Fall in Love With AI, and Other Life Rules for Graduates 'Over a longer period, productivity may suffer if the domestic economy is no longer gaining the positive spillovers,' the ECB's economists wrote. The ECB's research highlights the complexity of trade and investment relations between the eurozone and the U.S., and the outsized role played by Ireland in the trans-Atlantic economy. Many of the U.S. firms that contribute to the eurozone's surplus in goods are based in Ireland, and manufacture pharmaceuticals. But they also import services from the U.S. such as the use of intellectual property, while sending large profits back to their American shareowners. The ECB said that in 2024, the flows of goods, services and profits between the U.S. and the eurozone broadly evened out, even if the eurozone had a large surplus in the trade in goods. 'The euro area current account with the United States was nearly balanced in 2024, as the increasing surplus in goods trade was almost entirely offset by deficits in services trade and foreign direct investment income,' the ECB said. The eurozone operations of U.S. multinational enterprises contributed 'significantly' to those flows, the ECB said. Its economists estimated that 30% of the eurozone's surplus in goods was due to the sales of U.S. businesses, while those same companies accounted for 90% of the eurozone's services deficit. 'The widening goods trade surplus vis-à-vis the United States is driven mostly by a pronounced increase in exports of pharmaceutical products, which are mostly attributed to trade flows of Irish affiliates of U.S. MNEs,' the ECB said. While Ireland can offer skilled workers familiar with U.S. regulatory requirements to the pharmaceuticals industry, it is also attractive as a way of lowering their tax bills. President Trump has made it clear that he is unhappy that such a large share of pharmaceutical production for U.S. consumption is located overseas. The ECB's economists warned that higher tariffs on imports from the eurozone could lead U.S. businesses to move some of their production back home or to other locations. However, while that would reduce the size of the eurozone economy, the ECB said it would have a much smaller impact on employment and incomes because those activities are highly capital intensive rather than job-rich, and most of the profits are sent back to the U.S. Write to Paul Hannon at How Hackers Are Turning Tech Support Into a Threat SpaceX's Starship Explodes During Ground Test Oil Prices Rally, Stock Futures Fall in Holiday-Thinned Trading Food, Agriculture Leaders Sound Warnings on MAHA Overreach OpenAI Changes Price Structure for Business Version of ChatGPT Sign in to access your portfolio
Yahoo
36 minutes ago
- Yahoo
EU imposes medical device procurement restrictions on Chinese firms
The European Commission (EC) will restrict Chinese companies from EU government purchases of medical devices exceeding €5m ($5.7m). The move comes after a report found that 87% of public procurement contracts for medical devices in China were subject to 'exclusionary and discriminatory measures' and practices against EU-made medical devices and EU suppliers. In addition, Chinese entities will now be restricted from around 60% of annual spending within the medical device field, with EU contracting authorities now ordered to ensure that up to 50% of a contract's value is subcontracted to Chinese entities or includes Chinese-origin medical devices. Initiated in April 2024 with the findings published in January 2025, the report guiding the EU's decision marked the first investigation under the EU's International Procurement Instrument (IPI) regulation of 2022, a law created to promote reciprocity in access to international public procurement markets. China is the second-largest medtech market worldwide. The EU's investigation concluded that Chinese policies, including its 'Made in China 2025' economic roadmap, favoured domestic medical devices over imported ones by design. The EC also observed that China's volume-based procurement of medical devices forces bidders to offer the lowest possible price, and that the contracting authorities set a maximum reference price and maximum price margins for bid selection. The commission stated that the European procurement market is still one of the most open in the world, highlighting that Chinese medical device exports to the EU more than doubled between 2015 and 2023. The EC stated that it had made repeated efforts to engage with Chinese authorities regarding the lack of reciprocity and to seek a constructive and fair solution that would enable EU companies to access the Chinese market on terms comparable to those enjoyed by Chinese firms in the EU. However, the EC stated that China had 'so far not offered specific commitments that would address the discriminatory measures and practices identified'. The EC backed the restrictions earlier this month. Writing in state news outlet Xinhua, China's Ministry of Commerce (MoC) opposed the plans, branding the EU's move 'protectionist'. The ministry wrote: 'As responsible major economies, China and the EU should adhere to WTO [World Trade Organization] rules, uphold the principles of fairness, transparency and non-discrimination, address challenges through mutual openness, and resolve differences through cooperative dialogue to jointly safeguard the healthy development of China-EU economic and trade relations.' The EC stated that should China offer 'concrete, verifiable, and satisfactory solutions that effectively address the concerns identified', the IPI framework allows for the suspension or withdrawal of measures. Maroš Šefčovič, European Commissioner for Trade and Economic Security; Interinstitutional Relations and Transparency, commented: 'Our aim with these measures is to level the playing field for EU businesses. We remain committed to dialogue with China to resolve these issues.' "EU imposes medical device procurement restrictions on Chinese firms" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
